沈月雷本科毕业于武汉大学病毒学及分子生物学系，获中国食品药品检定研究院免疫学硕士，University of Massachusetts School of Medicine 免疫学博士，并于HHMI/纽约大学医学院Dan Littman实验室进行博士后训练。具有近25年的免疫学、分子生物学和基因敲除类模式动物制备和研究经验。2008年成立百奥赛图基因生物技术有限公司并担任董事长总经理。百奥赛图是一家以稳定、高效基因编辑技术平台为依托，以模式动物定制服务、重要模式动物开发与规模化繁殖与供应、体内药理药效评价服务、抗体药物研发外包服务为一体的高科技生物医药企业。公司秉承以追求更好的人类健康为宗旨，旨在为新药研发领域提供高品质的产品与服务。 公司总部现位于北京亦庄，在上海、江苏海门、美国波士顿设有分公司，同时在武汉、广州、成都等地设有办事处。
Dr. Yuelei Shen is President and CEO, Biocytogen Co Ltd. Dr. Shen received his BS degree from Wuhan University and his PhD in Immunology from the University of Massachusetts Medical School. He has over 25 years of research expertise in multiple disciplines including immunology, molecular biology, and mouse genetics. In 2008, Dr. Shen established Biocytogen Co Ltd, one of the pioneering biotech companies globally developing and producing Genetically Modified (GM) model animals for worldwide academic and pharmaceutical customers. Since then, Biocytogen’s business has expanded rapidly into preclinical services including PK/PD, in vivo efficacy, and toxicology, antibody drug discovery, and industrial scale animal breeding. Currently, Biocytogen’s world-class research and development team, strategically located in Beijing, Jiangsu, and Boston, is comprised of 800 high-achieving scientists, skilled technicians and highly efficient support staff.